Baker Ellis Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Baker Ellis Asset Management's VRTX Position: Q2 2026 in Review
Baker Ellis Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.32% in Q2 2026, selling an estimated $2.66K and leaving 1,846 shares worth $917K. The position accounts for 0.1% of the portfolio, ranked #129.
Baker Ellis Asset Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Baker Ellis Asset Management held 1,846 shares of Vertex Pharmaceuticals worth $917K as of Q2 2026.
- Baker Ellis Asset Management sold 6 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.66K.
- Vertex Pharmaceuticals made up 0.1% of Baker Ellis Asset Management's portfolio in Q2 2026, its #129 holding.
- Baker Ellis Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Baker Ellis Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.